Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 13/20 | 0.35 |
| ▸ | BRD4 | O60885 | 8/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.35 |
| ▸ | EP300 | Q09472 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BPTF | Q12830 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14885088 | 0.83 | NOTUM (0.38) | NOTUMSHMT2BAZ2BLMNAMAPT | |
| SCHEMBL25848676 | 0.80 | NAMPT (0.33) | — | |
| SCHEMBL25842594 | 0.78 | CGAS (0.39) | NOTUMMAPTCYP1A2 | |
| SCHEMBL25853945 | 0.77 | GRM5 (0.37) | — | |
| SCHEMBL10142864 | 0.77 | NOTUM (0.50) | NOTUMSHMT2CREBBPBAZ2BEP300 | |
| SCHEMBL25851654 | 0.76 | PDK2 (0.46) | — | |
| SCHEMBL25848915 | 0.76 | NPSR1 (0.30) | — | |
| SCHEMBL25847131 | 0.75 | PRMT5 (0.32) | — | |
| SCHEMBL25853250 | 0.75 | GRM5 (0.39) | LMNAMAPT | |
| SCHEMBL25851587 | 0.75 | ALDH1A1 (0.38) | LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |